Diagnosis and Ruling Out Look-Alikes
At a Glance
HPCA-associated dystonia is usually confirmed by finding two disease-causing HPCA variants, one on each gene copy, through genetic sequencing. A normal brain MRI does not confirm it, so clinicians also check for treatable mimics such as dopa-responsive dystonia and Wilson disease.
Diagnosing a rare condition like HPCA-associated dystonia requires careful evaluation. Because the symptoms—such as involuntary twisting and muscle contractions—overlap with many other conditions, doctors must actively rule out “look-alike” disorders that have specific, life-changing treatments. This page explains the advanced testing needed to establish a molecular diagnosis and the essential evaluations to ensure a treatable mimic hasn’t been missed.
Genetic Testing: Establishing the Diagnosis
Because HPCA-associated dystonia is so rare, it cannot be diagnosed through standard blood work or a physical exam alone. It usually requires looking at the genetic code to establish a molecular diagnosis [1].
- Advanced Sequencing: Variants may be detected by a dystonia gene panel, but most cases are definitively identified using Whole-Exome Sequencing (WES) or Whole-Genome Sequencing (WGS) [2][3].
- Inheritance Pattern: This is an autosomal recessive condition. Confirmation generally requires finding two pathogenic or likely pathogenic variants in the HPCA gene—usually shown to be in trans (one affecting each copy of the gene) [1]. Testing the biological parents (called trio testing) helps determine this inheritance pattern. However, a single variant or a “variant of uncertain significance” (VUS) does not confirm the diagnosis [2][4]. A clinical genetics professional should interpret the results.
- The Role of MRI: A standard brain MRI is typically “unremarkable” or normal [2]. A normal MRI does not confirm HPCA-associated dystonia by itself, but it is a helpful piece of evidence because the brain’s physical structure usually remains typical [2].
Ruling Out Treatable Look-Alikes
Before settling on an HPCA diagnosis, your medical team must ensure the symptoms are not caused by a “treatable mimic.” These are conditions that look like HPCA-associated dystonia but have specific treatments.
1. Dopa-Responsive Dystonia (DRD)
DRD is one of the most important conditions to rule out because it can be treated very effectively with a medication called levodopa [5].
- Clues: Symptoms often start in the legs, cause difficulty walking, and may get worse in the evening and better after sleep (diurnal fluctuation) [5][6].
- Testing: An age- and weight-appropriate, clinician-supervised levodopa trial of adequate duration is used to see if dystonia improves significantly [7]. Do not start or adjust levodopa without your treating clinician.
2. Wilson Disease
This is a rare but treatable disorder where copper builds up in the body, including the brain and liver [8].
- Clues: Along with movement issues, individuals may show changes in mood, behavior, or cognitive performance [8].
- Testing: The workup is individualized but often involves checking levels of ceruloplasmin (a protein that carries copper) and performing a 24-hour urinary copper test [8][9]. A single normal test does not exclude the disease, and doctors may also look for mutations in the ATP7B gene.
3. Inherited Manganese-Transport Disorders
These are very rare conditions (involving the SLC30A10 or SLC39A14 genes) where the body cannot properly manage manganese [10].
- Clues: These can look like dystonia but are often associated with liver issues or a high red blood cell count (polycythemia) [11][12].
- Testing: A specialist will interpret blood tests for manganese levels. On an MRI, these conditions often show a very specific bright signal in the basal ganglia, distinguishing them from HPCA variants [11][13].
Examples to Discuss with Your Specialist
The workup for dystonia must be individualized to the patient’s age and presentation. Use these examples as discussion prompts with your neurologist to ensure a complete evaluation:
- Brain MRI: Was it normal, and does it help rule out structural or metabolic causes? [2]
- Levodopa Trial: Has a supervised trial of adequate dose and duration been completed to rule out DRD? [7]
- Copper Studies: Have tests for Wilson disease (like ceruloplasmin or urinary copper) been considered? [8]
- Manganese Level: Is testing for manganese disorders appropriate? [10]
- Genetic Sequencing: Are the genetic results clear (e.g., two pathogenic variants in trans), or is reanalysis needed? [2][4]
Common questions in this guide
What genetic testing is used to diagnose HPCA-associated dystonia?
Does finding one HPCA variant confirm DYT2 dystonia?
What does a normal brain MRI mean in HPCA-associated dystonia?
Why might my doctor recommend a levodopa trial?
How is Wilson disease evaluated in someone with dystonia?
What clues suggest a manganese transport disorder instead?
Get notified when new evidence is published on Primary dystonia, DYT2 type.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
Case Report of Pediatric HPCA-Associated Dystonia: Analysis of Ca2+ and K+ Channel Dynamics and Experience With Pallidal Deep Brain Stimulation.
Nou-Fontanet L, Ousingsawat J, Aziz M, et al.
Pediatric neurology 2025; (172()):46-52 doi:10.1016/j.pediatrneurol.2025.07.020.
PMID: 40884872 - 2
Childhood-Onset Choreo-Dystonia Due to a Recurrent Novel Homozygous Nonsense HPCA Variant: Case Series and Literature Review.
Magrinelli F, Bhatia KP, Beiraghi Toosi M, et al.
Movement disorders clinical practice 2023; (10(1)):101-108 doi:10.1002/mdc3.13529.
PMID: 36698997 - 3
Specific Cognitive Changes due to Hippocalcin Alterations? A Novel Familial Homozygous Hippocalcin Variant Associated with Inherited Dystonia and Altered Cognition.
Siegert S, Schmidt WM, Pletschko T, et al.
Neuropediatrics 2021; (52(5)):377-382 doi:10.1055/s-0040-1722686.
PMID: 33511595 - 4
Abrupt-onset cervico-truncal dystonia after Mycoplasma pneumoniae infection: Unmasking a possible CACNA1A-related susceptibility.
Morelli M, Pedullà G, Trimboli M, et al.
Parkinsonism & related disorders 2026; (149()):108397 doi:10.1016/j.parkreldis.2026.108397.
PMID: 42335824 - 5
Case Report: Guitarist's cramp as the initial manifestation of dopa-responsive dystonia with a novel heterozygous GCH1 mutation.
Hasegawa T, Hosaka T, Harada R, et al.
F1000Research 2021; (10()):361 doi:10.12688/f1000research.51433.1.
PMID: 34394914 - 6
Clinical Management of Dystonia in Childhood.
Luc QN, Querubin J
Paediatric drugs 2017; (19(5)):447-461 doi:10.1007/s40272-017-0243-3.
PMID: 28620849 - 7
Clinical and Basic Research on Dopa-Responsive Dystonia: Neuropathological and Neurochemical Findings.
Furukawa Y
Juntendo medical journal 2025; (71(1)):2-10 doi:10.14789/ejmj.JMJ24-0023-R.
PMID: 40109402 - 8
Cryptic Presentations of Neurologic Wilson Disease With ATP7B Peptide Assessments.
Penon-Portmann M, Tapia C, Patterson KC, et al.
Neurology. Genetics 2026; (12(6)):e200421 doi:10.1212/NXG.0000000000200421.
PMID: 42960203 - 9
Clinical and neuroimaging phenotypes of genetic parkinsonism from infancy to adolescence.
Morales-Briceño H, Mohammad SS, Post B, et al.
Brain : a journal of neurology 2020; (143(3)):751-770 doi:10.1093/brain/awz345.
PMID: 31800013 - 10
Consensus of Expert Opinion for the Diagnosis and Management of Hypermanganesaemia With Dystonia 1 and 2.
Fang S, Clayton PT, Garg D, et al.
Journal of inherited metabolic disease 2025; (48(3)):e70031 doi:10.1002/jimd.70031.
PMID: 40320765 - 11
Pediatric Case Series with Early-Onset Dystonia: Clinical Clues of Inherited Manganese Transporter Defects.
Hopurcuoglu D, Zubarioglu T, Akgun A, et al.
Annals of Indian Academy of Neurology 2026; (29(1)):94-97 doi:10.4103/aian.aian_683_25.
PMID: 41724673 - 12
A novel mutation in SLC39A14 causing hypermanganesemia associated with infantile onset dystonia.
Juneja M, Shamim U, Joshi A, et al.
The journal of gene medicine 2018; (20(4)):e3012 doi:10.1002/jgm.3012.
PMID: 29498153 - 13
Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation.
Zaki MS, Issa MY, Elbendary HM, et al.
Clinical genetics 2018; (93(4)):905-912 doi:10.1111/cge.13184.
PMID: 29193034
This page is for informational purposes only and does not constitute medical advice about HPCA-associated dystonia. Your neurologist and genetics professional should interpret genetic results and decide which mimic tests are appropriate for you.